Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways

Translational Research

Volumn 160, Issue 2, 2012, Pages 125-130

  Cameron, Jamie ^a   Bogsrud, Martin P ^a   Tveten, Kristian ^a   Strom, Thea Bismo ^a   Holven, Kirsten ^a   Berge, Knut Erik ^a   Leren, Trond P ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SCAVENGER RECEPTOR; SUBTILISIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL SURFACE; CLEARANCE; CONTROLLED STUDY; ENDOTHELIUM CELL; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LIVER SINUSOID; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS;

EID: 84863912769     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2012.01.010     Document Type: Article

References (28)

1. J.L. Goldstein, H.H. Hobbs, and M.S. Brown Familial hypercholesterolemia C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, The Metabolic & Molecular Bases of Inherited Disease 2001 McGraw-Hill New York 2863 2913
2. K.N. Maxwell, and J.L. Breslow Adenoviral-mediated expression of PCSK9 in mice results in a low-density lipoprotein receptor knockout phenotype Proc Natl Acad Sci U S A 101 2004 7100 7105 (Pubitemid 38596449)
3. S.W. Park, Y.A. Moon, and J.D. Horton Post-transcriptional regulation of low-density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver J Biol Chem 279 2004 50630 50638 (Pubitemid 39577880)
4. S.A. Mousavi, K.E. Berge, and T.P. Leren The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis J Intern Med 266 2009 507 519
5. D.W. Zhang, T.A. Lagace, and R. Garuti Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of the low density lipoprotein receptor decreases receptor recycling and increases degradation J Biol Chem 282 2007 18602 18612 (Pubitemid 47100234)
6. Y.W. Qian, R.J. Schmidt, and Y. Zhang Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis J Lipid Res 48 2007 1488 1498 (Pubitemid 47312011)
7. Z. Zhao, Y. Tuakli-Wosornu, and T.A. Lagace Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote Am J Hum Genet 79 2006 514 523 (Pubitemid 44384260)
8. A.J. Hooper, A.D. Marais, D.M. Tanyanyiwa, and J.R. Burnett The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population Atherosclerosis 193 2007 445 448 (Pubitemid 47058112)
9. S.G. Lakoski, T.A. Lagace, J.C. Cohen, J.D. Horton, and H.H. Hobbs Genetic and metabolic determinants of plasma PCSK9 levels J Endocrinol Metab 94 2009 2537 2543
10. Q. Cui, X. Ju, and T. Yang Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population Atherosclerosis 213 2010 632 636
11. A. Zaid, A. Roubtsova, and R. Essalamni Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration Hepatology 48 2008 646 654
12. A. Grefhorst, M.C. McNutt, T.A. Lagace, and J.D. Horton Plasma PCSK9 preferentially reduces liver LDL receptors in mice J Lipid Res 49 2008 1303 1311
13. T. Seternes, K. Sorensen, and B. Smedsrod Scavenger endothelial cells of vertebrates: a nonperipheral leucocyte system for high-capacity elimination of waste macromolecules Proc Natl Acad Sci U S A 99 2002 7594 7597 (Pubitemid 34568736)
14. B. Smedsrod, H. Pertoft, S. Gustavson, and T.C. Laurent Scavenger functions of the liver endothelial cells Biochem J 266 1990 313 327 (Pubitemid 20090127)
15. T.J.C. Van Berkel, Y.B. De Rijke, and J.K. Kruijt Different fate in vivo of oxidatively modified low density lipoprotein and acetylated low density lipoprotein in rats J Biol Chem 266 1991 2282 2289
16. R. Li, A. Oteiza, and K.K. Sorensen Role of liver sinusoidal endothelial celles and stabilins in elimination of oxidized low-density lipoproteins Am J Gastrointest Liver Physiol 300 2011 G71 G81
17. T.P. Leren, T. Manshaus, and U. Skovholt Application of molecular genetics for diagnosing familial hypercholesterolemia in Norway: results from a family-based screening program Semin Vasc Med 4 2004 75 85 (Pubitemid 38393294)
18. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge Clin Chem 18 1972 401 408
19. H. Li, S.W. Park, H.S. Lee, W. Chen, and J. Liu Hepatocyte nuclear factor 1α plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine J Biol Chem 284 2009 28885 28895
20. D. Fan, P.G. Yancey, and S. Qiu Self-association of human PCSK9 correlates with its LDLR-degrading activity Biochemistry 47 2008 1631 1639 (Pubitemid 351231213)
21. T.S. Fisher, P. Lo Surdo, and S. Pandit Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation J Biol Chem 282 2007 20502 20512 (Pubitemid 47100016)
22. T.A. Lagace, D.E. Curtis, and R. Garuti Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice J Clin Invest 116 2006 2995 3005 (Pubitemid 44684484)
23. P. Boucher, and J. Herz Signaling through LRP1: protection from atherosclerosis and beyond Biochem Pharmacol 81 2011 1 5
24. T.E. Willnow, S.A. Armstrong, R.E. Hammer, and J. Herz Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo Proc Natl Acad Sci U S A 92 1995 4537 4541
25. C. Le May, S. Kourimate, and C. Langhi Proprotein convertase subtilisin/kexin type 9 null mice are protected from postprandial triglyceridemia Arterioscler Thromb Vasc Biol 29 2009 684 690
26. G. Lambert, N. Ancellin, and F. Charlton Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment Clin Chem 54 2008 1038 1045 (Pubitemid 351793411)
27. J. Mayne, A. Raymond, and A. Chaplin Plasma PCSK9 levels correlate with cholesterol in men but not in women Biochem Biophys Res Commun 361 2007 451 456 (Pubitemid 47193117)
28. S.E. Humphries, R.D. Neely, and R.A. Whittall Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9 Clin Chem 55 2009 2153 2161